Sansure Biotech Inc (688289) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sansure Biotech Inc (688289) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥59.72 Million ≈ $8.74 Million USD) by net assets (CN¥7.22 Billion ≈ $1.06 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sansure Biotech Inc net asset quality index to measure how much of total assets are equity-financed.
Sansure Biotech Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Sansure Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Sansure Biotech Inc to evaluate the quality of earnings relative to operating cash generation.
Sansure Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sansure Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Qingdao Yunlu Advanced Materials Technology Co. Ltd. A
SHG:688190
|
N/A |
|
Beijing Creative Distribution Automation Co Ltd
SHE:002350
|
0.034x |
|
Advantage Oil & Gas Ltd.
TO:AAV
|
0.048x |
|
Jiangsu Bide Science and Technology Co. Ltd.
SHG:605298
|
0.025x |
|
Hwa Create Corp Ltd
SHE:300045
|
0.000x |
|
Ingenia Communities Group
AU:INA
|
0.045x |
|
OC Oerlikon Corp AG
SW:OERL
|
0.208x |
|
Heineken Bhd
KLSE:3255
|
0.423x |
Annual Cash Flow Conversion Efficiency for Sansure Biotech Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Sansure Biotech Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Sansure Biotech Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥16.75 Billion ≈ $2.45 Billion |
CN¥183.96 Million ≈ $26.92 Million |
0.011x | -70.60% |
| 2024-12-31 | CN¥7.35 Billion ≈ $1.07 Billion |
CN¥274.45 Million ≈ $40.16 Million |
0.037x | +145.88% |
| 2023-12-31 | CN¥7.42 Billion ≈ $1.09 Billion |
CN¥112.82 Million ≈ $16.51 Million |
0.015x | -95.54% |
| 2022-12-31 | CN¥7.51 Billion ≈ $1.10 Billion |
CN¥2.56 Billion ≈ $374.45 Million |
0.341x | +15.80% |
| 2021-12-31 | CN¥6.38 Billion ≈ $933.79 Million |
CN¥1.88 Billion ≈ $274.67 Million |
0.294x | -47.17% |
| 2020-12-31 | CN¥4.75 Billion ≈ $694.40 Million |
CN¥2.64 Billion ≈ $386.65 Million |
0.557x | +1285.39% |
| 2019-12-31 | CN¥557.48 Million ≈ $81.58 Million |
CN¥22.41 Million ≈ $3.28 Million |
0.040x | +58.21% |
| 2018-12-31 | CN¥396.29 Million ≈ $57.99 Million |
CN¥10.07 Million ≈ $1.47 Million |
0.025x | +115.67% |
| 2017-12-31 | CN¥378.99 Million ≈ $55.46 Million |
CN¥-61.44 Million ≈ $-8.99 Million |
-0.162x | -- |
About Sansure Biotech Inc
Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tr… Read more